Form 4: Baker Bros. Advisors LP Reports Acquisition of Kodiak Sciences Stock Options

Baker Bros. Advisors LP reports the acquisition of 40,000 non-qualified stock options in Kodiak Sciences Inc. on June 28, 2024, with Felix J. Baker receiving the grant as a director.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 regarding transactions in Kodiak Sciences Inc. (KOD) securities.
• On June 28, 2024, Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC and a director of Kodiak Sciences, was granted 40,000 non-qualified stock options.
• The options have a strike price of $2.35 per share and expire on June 27, 2034.
• The options vest on the earlier of the first anniversary of the grant date or one day prior to the next annual meeting of stockholders, contingent on Felix J. Baker's continued service on the board.
• The filing also clarifies the indirect beneficial ownership of these options by various Baker Bros. entities, including 667, L.P. and Baker Brothers Life Sciences, L.P.
• The Baker Bros. entities disclaim beneficial ownership except to the extent of their pecuniary interest.
• Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options due to their ownership interest in the general partners of the Funds.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a standard regulatory filing reporting stock option grants. There are no explicit positive or negative implications for the company's performance.

Positives

• The grant of stock options to a director aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

This filing is a routine disclosure of insider transactions, common in the biopharmaceutical industry where equity compensation is frequently used to incentivize executives and directors.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and strike price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates